RxDoctor Payments Data

Stacy Hardy, MD

Internal Medicine · McAlester, OKNPI 1396708517

Payments from drug & device makers

$3,405in general payments, 2019–2025

Across 227 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$776
  • Novo Nordisk$457
  • AbbVie$410
  • Pfizer$323
  • AstraZeneca$275
  • Boehringer Ingelheim$155
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,405 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$165,247
Medicare patients
602
Services billed
3,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide149$180,771
EliquisApixaban142$116,525
Tresiba Flextouch U-200Insulin Degludec27$31,517
XareltoRivaroxaban32$27,830
MyrbetriqMirabegron26$24,758
JardianceEmpagliflozin22$24,372
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$22,314
GemtesaVibegron16$19,155
MounjaroTirzepatide14$18,452
VraylarCariprazine Hcl12$16,150
EntrestoSacubitril/Valsartan13$15,028
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen395$10,132
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$9,077
JanuviaSitagliptin Phosphate17$8,691
Breo ElliptaFluticasone/Vilanterol22$8,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$457$180,771149 claims
PfizerEliquis, Premarin$323$122,336155 claims
GSKTrelegy Ellipta, Breo Ellipta$776$30,43256 claims
Johnson & JohnsonXarelto$12$27,83032 claims
Boehringer IngelheimJardiance$155$24,37222 claims
Sumitomo Pharma America, Inc.Gemtesa$110$19,15516 claims
AbbVieVraylar, Synthroid$410$18,54647 claims
Lilly USA, LLCMounjaro$66$18,45214 claims
AstraZenecaNexium$275$3,24813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in McAlester

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →